DOI: 10.1055/s-00000054

Pharmacopsychiatry

Ausgabe 01 · Volume 18 · Januar 1985 DOI: 10.1055/s-002-10193

EDITORIAL

1
Netter, P.; Beckmann, H.: Congress of the AGNP, Nuremberg 1983

GERONTOPSYCHIATRY

2
Heimann, H.: Clinical Aspects of Dementia Syndrome

6
Häfner, H.: Mental Disorder in Old Age - Medical and Social Risk Factors
12
Koeppen, D.; Netter, P.; Fischer, C.: Individual Differences in the Effects of Clobazam on Memory Functions - Clobazam and Memory
15
Albus, M.; Ackenheil, M.; Engel, R. R.; Müller-Spahn, F.; Stahl, S.: Influence of Beta-Blockers and/or Minor Tranquilizers on Autonomic Stress Reactions
17
Depoortere, H.: A Comparative EEG Study of Some Benzodiazepine (BZD) and Non-BZD Sedative or Hypnotic Drugs
20
Hoff, P.; Dieterle, D.; Eben, E.: The Effect of CGP 361 A, a New Beta-blocking Compound, on In-patients with Anxiety
22
Ruhland, M.: Metaclazepam - a New Anxiolytic Benzodiazepine with Selective Tolerance and Crosstolerance to Other Benzodiazepines
24
Richter, W.; Giertz, H.: The Effect of Supidimide and Lormetazepam on Sleep - A Controlled Clinical Study in Outpatients
27
Dirschedl, P.; Hasford, J.: Drug Monitoring of Psychiatric Patients: Methodological Aspects
29
Strauss, A.; Scherer, J.; Friedl, F.; Rüther , E.: The Importance of the Quantitative Description of Drug Therapy for Drug Surveillance in Psychiatry
31
Grohmann, R.; Scherer, S.; Schmidt, L. G.: Adverse Drug Reactions in Psychiatric Inpatients
33
Oefele, K. v; Rüther, E.: Adverse Drug Reaction Monitoring in Long-Term Psychiatric Inpatients
35
Haag, H.; Greil, W.; Haag, M.; Bender, W.; Rüther, E.: Tardive Dyskinesia and Medication History
37
Wolf, B.; Rüther, E.: Drug Abuse and Dependence in Psychiatric Inpatients
40
Schmidt, L. G.; Schüssler, G.; Linden, M.; Müller-Oerlinghausen, B.: Impact of Adverse Drug Reactions on Treatment of Psychiatric Outpatients
42
Bürke, H.: Drug Monitoring in Psychiatric Outpatient Treatment
44
Linden, M.; Schüssler, G.: Low Dosage Antidepressant Treatment in Private Psychiatric Practice - A Replication Study
46
Balss, G.; Berzewski, H.: The Attitude and Judgment of Psychiatrists in Private Practice in Assessing the Effect of Psychopharmaceuticals
48
Müller, J.; Hertrampf, R.; Müller-Oerlinghausen, B.: Exact Costs and Clinical Impact of Routine Assessments of Psychotropic Drug Serum Levels in a Psychiatric Hospital
52
Möller, H. J.; Scharl, W.; von Zerssen, D.: Can the Result of Neuroleptic Treatment be Predicted?
An Empirical Investigation on Schizophrenic Inpatients
54
Schöllnhammer, G.; Spechtmeyer, H.; Hesse, C.; Husser, J.; Ebeling, H.; Parish, H. M.: Plasma Levels and Pharmacokinetics of Benperidol in Dog and Man
56
Schmidt, W. J.: How Neuroleptics Control Fixed Action Patterns
58
Schmauss, M.; Lange, E.; Nedopil, N.; Rüther, E.; Weiss-Brummer, J.: Effect of the Neuroleptic EMD 30-533 on Schizophrenic Symptoms: An Open Study
61
Auberger, S.; Greil, W.; Rüther, E.: Tiapride in the Treatment of Tardive Dyskinesia
A Double-blind Study
63
Nedopil, N.; Eben, E.; Klein, H.; Krüger, R.; Rüther, E.; Schmauss, M.: High-dosage Neuroleptic Therapy for Acute Schizophrenic Patients - Two Double-blind Studies with Benperidol
67
Albus, M.; Ackenheil, M.; Müller-Spahn, F.; Naber, D.; Welter, D.: Do Norepinephrine Serum Levels Predict the Effects of Neuroleptic Withdrawal on Psychopathology?
69
Eben, E.; Rüther, E.: Animal Trial Prediction and Clinical Effect of New Chemical Substances to be Used as Antipsychotic Agents
71
Bürki, H. R.; Alder, J.; Eichenberger, E.: Effect of Fluperlapine on Dopaminergic Mechanisms in Rat Brain
73
Woggon, B.; Heinrich, K.; Küfferle, B.; Müller-Oerlinghausen, B.; Pöldinger, W.; Rüther, E.; Schied, H. W.: Fluperlapine - a Potential Successor to Clozapine
75
Arendt, G.; Heinrich, K.; Tegeler, J.; Wöller, W.; Quadbeck, H.; Klieser, E.; Lange, H.; Bremberger, R.: Clinical Side-Effects under Fluperlapine Therapy
78
Tegeler, J.: A Comparative Trial of CIS(Z)-clopenthixol-decanoate and Fluphenazine-decanoate
83
Ott, G.; Ott, C.: Study on the Effectiveness of Trazodone in the Treatment of Endogenous Depression. Pharmacokinetic and Psychopathometric Investigations
86
Schmauss, M.; Laakmann, G.; Dieterle, D.; Schmitz, R.; Wittmann, M.: Clinical Investigation on the Importance of NE-Reuptake Inhibition for Antidepressive Efficacy: Oxaprotiline versus its R-enantiomer CGP 12-103/A
88
Schmauss, M.; Laakmann, G.; Dieterle, D.: Nomifensine: A Double-blind Comparison of Intravenous versus Oral Administration in Therapy - Resistant Depressed Patients
91
Baumann, P.; Gaillard, J.-M.; Jonzier-Perey, M.; Gerber, C.; Bouras, C.: Hydroxylated Metabolites of Amitriptyline in Rat Brain After Repeated Administration of the Parent Drug
94
Kern, U.; Richter, W.: Clinical Comparison of Etoperidone and Amitriptyline in Endogenous Depressive Patients
96
Kissling, W.; Möller, H. J.; Lauter, H.; Binz, Ursula; Wendt, G.: Double-Blind Comparison of Intravenous Versus Oral Maprotiline*. Antidepressant Activity, Plasma Levels, Side-Effects
98
Woggon, B.; Angst, J.; Curtius, H. Ch.; Niederwieser, A.; Levine, R. A.; Borbély, A. A.; Tobler, I.: Tetrahydrobiopterin (BH4) in Endogenous Depression
100
Müller-Oerlinghausen, B.; Fähndrich, E.: The Relationship between Pharmacokinetic Data and the Clinical Response in Patients treated with Maprotiline or Clomipramine by Intravenous Infusion
102
Kropf, D.; Müller-Oerlinghausen, B.: Assessment of Visual Perception by Means of the Signal Detection Theory in Patients under Lithium Long-term Treatment*
104
Kropf, D.; Müller-Oerlinghausen, B.: The Influence of Lithium Long-term Medication on Personality and Mood*
106
Greil, W.; Bauer, J.; Breit, J.; Haag, M.: Single Daily Dose Schedule in Lithium Long-Term Treatment: Effects on Pharmacokinetics and on Renal and Cardiac Functions
108
Fähndrich, E.; Herrmann, W. M.: The Search for Electro-Encephalographic Variables which could Predict the Efficacy of Antidepressants
110
Trachsler, E.; Höchli, D.; Luckner, N. v; Woggon, B.: Dexamethasone Suppression Test before and after Partial Sleep Deprivation in Depressed Schizophrenic and Schizoaffective Patients
114
Maier, W.; Philipp, M.: Improving the Assessment of Severity of Depressive States: A Reduction of the Hamilton Depression Scale
116
Wacker, H. R.; Battegay, R.: What do Psychiatric Outpatients Think about Psychopharmacotherapy?
118
Wendt, G.; Binz, U.; Müller, A. A.: KUSTA (Kurz-Skala Stimmung/Aktivierung): A Daily Self-rating Scale for Depressive Patients
123
Sittig, W.; Kleindienst, G.; Irmisch, R.: Effects of Food Intake on CNS Activity, Psychomotor Performance and Mood States in Healthy Volunteers
127
Müller, A. A.; Binz, U.; Wendt, G.: Aspects of the Interpretation of Placebo-controlled Clinical Trials
129
Baumann, U.; Rösler, F.: The Effect of Different Instructions with Different Drugs (Placebos, Tranquilizers)
131
Classen, W.; Feingold, E.: Use of Placebos in Medical Practice
133
Schwalb, H.; Schimana, W.: Mortality in Hospitalized Psychiatric Patients
(First Results of a 10-Year Study)
134
Höchli, D.; Trachsler, E.; Luckner, N. v; Woggon, B.: Partial Sleep Deprivation Therapy of Depressive Syndromes in Schizophrenic Disorders
138
Jänicke, U.-A.; Hefer, B.; Coper, H.: The Variable Maze: A Procedure for Testing Cognitive and Memory Performance and their Drug or Age Induced Changes
141
Menge, H. G.; Brand, U.; Kley, H.-P.: Classification of New CNS-active Compounds by a Two-lever Drug Discrimination Procedure
143
Kapfhammer, H.-P.; Kuss, H.-J.; Eben, E.; Rüther, E.: L-dopa Infusion Experiments in Combination with the L-dopa-decarboxylase Inhibitors Benserazide and Carbidopa: L-dopa Metabolism and Neuroendocrinological Effects
145
Reuß, F.; Schley, J.; Müller-Oerlinghausen, B.: The Relation between Serum Concentration of α1-acid Glycoprotein and Clinical Characteristics of Patients Treated with Perazine
147
Fröhler, M.; Saito, Y.; Ackenheil, M.; Bak, R.; Bondy, B.; Feistenauer, E.; Hofschuster, E.; Vakis, A.; Welter, D.: Catecholaminergic Binding Sites on Blood Cells of Healthy Volunteers with Special Respect to Circadian Rhythms
149
Bondy, B.; Ackenheil, M.; Bak, R.; Feistenauser, E.; Fröhler, M.: Catecholamine - Receptors on Blood Cells of Untreated Schizophrenic Patients
151
Syha, K.: Methodical Problems with α2-Receptor-binding Studies on Membrane Fragments of Blood Platelets in Clinical Investigations
153
Rommelspacher, H.; Schmidt, L.: Increased Formation of β-carbolines in Alcoholic Patients following Ingestion of Ethanol
156
Rickels, K.: Clinical Pharmacology of Benzodiazepines
160
Sieghart, W.: Binding of Various Benzodiazepine Receptor Ligands to Different Benzodiazepine Receptor Subtypes
163
Haefely, W.: Pharmacology of Benzodiazepine Antagonists
167
Stephens, D. N.; Kehr, W.; Wachtel, H.; Schmiechen, R.: The Anxiolytic Activity of β-Carboline Derivatives in Mice, and its Separation from Ataxic Properties
171
Emrich , H. M.; Lund, R.: Effect of the Benzodiazepine Antagonist Ro 15-1788 on Sleep after Sleep Withdrawal
174
Ruhland, M.; Liepmann, H.; Muesch, H. R.: 1.2-Anellated 1.4-Benzodiazepine Derivatives - A New Class of Antipsychotics

BENZODIAZEPINES

10
Müller, E.: Benzodiazepine Receptor Interactions of Arfendazam, a Novel 1,5-Benzodiazepine*

DRUG SURVEILLANCE IN PSYCHIATRY

26
Helmchen, H.; Rüther, E.: Introduction

NEUROLEPTIC DRUGS

50
Möller, H. J.; Follmann, U.; Scharl, W.; von Zerssen, D.: Background Variables of Depressive States upon Discharge of Schizophrenic Inpatients Treated with Neuroleptics

ANTIDEPRESSANT DRUGS AND LITHIUM

80
Ott, C.; Ott, G.: Clinical Study of Trazodone in the Treatment of Patients with Endogenous Depression. Monitoring by Means of Psychopathometric Tests

PSYCHOLOGICAL ASSESSMENT AND NON-DRUG FACTORS IN PHARMACOTHERAPY

112
Philipp, M.; Maier, W.: Operational Diagnosis of Endogenous Depression. I. Comparison with Clinical Diagnosis

PHARMACOLOGY - BIOCHEMISTRY

136
Jänicke, B.; Wrobel, D.; Schulze, G.: The Effects of Various Drugs on the Motor Performance Capacity of Old Rats

BENZODIAZEPINES: AGONISTS AND ANTAGONISTS

155
Hippius, H.; Emrich, H. M.: Introduction